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ABSTRACT 
This paper reports a paper-based microfluidic competitive immunoassay for the detection of 
mephedrone, a new psychoactive substance (NPS).  Using the proposed system, limits of detection of 
4.078 µg mL-1 and 1.597 µg mL-1 for aqueous mephedrone and spiked urine samples, respectively, were 
obtained, with these values enabling the detection of clinically relevant concentrations of mephedrone.  
The proposed device has the opportunity to provide rapid, on-site testing, within either a forensic or 
clinical setting, for NPSs.  
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INTRODUCTION 
Mephedrone (Figure 1: 2, R = Me) is a synthetic cathinone that 
has emerged in drug seizures as a replacement for controlled stimu-
lants including amphetamines such as methamphetamine and 3,4-
methylenedioxymethamphetamine (MDMA).  The analysis of drugs 
of abuse from biological matrices using microfluidic devices has 
mainly focused on extraction and separation of samples, as presented 
in a review by Al-Hetlani [1].  For example, micellar electrokinetic 
capillary chromatography and laser-induced fluorescence has been 
used to separate and detect amphetamine and analogous compounds 
including cathinone (3), methcathinone (2, R = H), ephedrine and 
norephedrine [2]. However, microfluidic immunoassays have also 
been reported as rapid screening tests for banned substances including morphine [3], cocaine [3] and 
methamphetamine [4] but they have not yet been applied to NPSs. 
 
EXPERIMENTAL 
Paper microfluidic devices were printed onto Whatman Grade 1 filter paper using a Xerox Phaser 
8500 solid ink printer and then placed in an oven at 130ºC for 180 seconds to melt the wax.  The design 
of the device was adopted from Ge et al. [5], and an overall reaction scheme is provided in Figure 2. 
The reaction wells of the microfluidic device were then activated using chitosan and glutaraldehyde 
prior to addition of the anti-methcathinone antibody.  The wells were then blocked with 1% milk pow-
der in phosphate buffered saline (PBS) and devices were either used immediately or stored at 4°C for a 
period of up to 4 weeks prior to use in a stability study.  Aqueous or biological (urine) samples were 
mixed 50:50 with horseradish peroxidase (HRP)-conjugated cathinone (produced using a HRP conju-
gation kit [Abcam, UK]).  Colourimetric detection was then achieved through addition of 3,3’,5,5’-
tetramethylbenzidine (TMB) and intensity values examined using Image J.  
 
 
Figure 2:  Overall schematic showing preparation of the paper microfluidic devices including i) wax printing,     
ii) antibody addition and iii) colourimetric detection and analysis using Image J.  Design adapted from [5].  
Figure 1: Synthesis of mephedone 
and its primary metabolite. 
RESULTS AND DISCUSSION 
Mephedrone hydrochloride (2, R = Me) and its corresponding metabolite (4) were synthesized from 
(1) using the method by Santali et al. (Figure 1).  Initial experiments showed that optimum results were 
obtained using an antibody concentration of 0.7068 ng mL-1 and labelled-antigen concentration of 7.083 
ng mL-1.  Mephedrone containing samples were prepared from both aqueous media and spiked urine to 
represent the drug in both its pure form and as a clinical specimen.  Regression analysis showed limits 
of detection (LOD) of 4.078 µg mL-1 and 1.597 µg mL-1 for the aqueous mephedrone and spiked urine 
samples, respectively.  Comparing these values with clinically relevant concentrations for mephedrone 
in urine (LOD = 2 µg/mL and LOQ = 4 µg/mL) shows that this method has good sensitivity [6].  A 
comparison was then made using mephedrone, cathinone (3) and the principle metabolite of 
mephedrone (4-methylephedrine, 3) (Figure 3).  Stability and reproducibility of devices was examined 
and showed no significant different in signal intensity recorded over four weeks (Between ANOVA: F 
(3, 47) = 1.682, p = 0.185) and no significant difference within or between devices (Figure 4). 
 
 
Figure 3: Comparison of the analysis of urine sam-
ples spiked with cathinone (3, ), mephedrone          
(2, R=Me, ) and its main metabolite, 4-meth-
ylephedrine (4, ).   
 
 
 
 
Figure 4: Inter-chip variability study showing sig-
nal intensity values recorded across four different 
microfluidic device. No significant different (Be-
tween ANOVA for 1:32,000: F (3, 47) = 2.103,     p 
= 0.114). Variation within individual microfluidic 
devices also assessed using Levene’s test, which in-
dicated equal variances (p = 0.638) (n=12).  
 
CONCLUSION 
The paper microfluidic device presented has the opportunity to provide rapid, on-site testing, within 
either a forensic or clinical setting, for NPSs.  
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